- Home
- BCSF vs CVAC Comparison
BCSF vs CVAC Comparison
Compare BCSF & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCSF
- CVAC
- Stock Information
- Founded
- BCSF 2015
- CVAC 2000
- Country
- BCSF United States
- CVAC Germany
- Employees
- BCSF N/A
- CVAC N/A
- Industry
- BCSF Finance/Investors Services
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- BCSF Finance
- CVAC Health Care
- Exchange
- BCSF Nasdaq
- CVAC Nasdaq
- Market Cap
- BCSF 1.0B
- CVAC 818.8M
- IPO Year
- BCSF 2018
- CVAC 2020
- Fundamental
- Price
- BCSF $15.12
- CVAC $3.47
- Analyst Decision
- BCSF Hold
- CVAC Strong Buy
- Analyst Count
- BCSF 4
- CVAC 2
- Target Price
- BCSF $16.50
- CVAC $14.00
- AVG Volume (30 Days)
- BCSF 292.4K
- CVAC 535.9K
- Earning Date
- BCSF 05-05-2025
- CVAC 05-22-2025
- Dividend Yield
- BCSF 0.79%
- CVAC N/A
- EPS Growth
- BCSF N/A
- CVAC N/A
- EPS
- BCSF 1.74
- CVAC 0.75
- Revenue
- BCSF $284,993,000.00
- CVAC $554,073,921.00
- Revenue This Year
- BCSF N/A
- CVAC N/A
- Revenue Next Year
- BCSF N/A
- CVAC $38.07
- P/E Ratio
- BCSF $8.72
- CVAC $4.65
- Revenue Growth
- BCSF N/A
- CVAC 895.54
- 52 Week Low
- BCSF $13.20
- CVAC $2.22
- 52 Week High
- BCSF $19.21
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- BCSF 46.65
- CVAC 56.52
- Support Level
- BCSF $14.69
- CVAC $3.26
- Resistance Level
- BCSF $15.58
- CVAC $3.63
- Average True Range (ATR)
- BCSF 0.38
- CVAC 0.21
- MACD
- BCSF 0.07
- CVAC 0.01
- Stochastic Oscillator
- BCSF 50.00
- CVAC 51.83
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan among others.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.